News

Marqibo, a sphingomyelin/cholesterol liposome-encapsulated formulation of vincristine sulfate, is administered at a dose of 2.25 mg/m2 intravenously over 1 hour once every 7 days. Marqibo is intended for

Based on the achievement of pre-determined milestones, the company will receive $1.5m in funding for the first of five years. In addition, DARPA is funding for the development

AEZS-130, which has been granted orphan drug designation by the FDA, is an orally-active small molecule that stimulates the secretion of adult growth hormone. The company has completed

The companies are to initiate a third Phase III study of laquinimod, following the written agreement reached with the FDA on the Special Protocol Assessment. Teva Pharmaceutical Industries

The objective of the Phase IIa multicentre, placebo-controlled trial, which has enrolled 53- patients, divided in 3 cohorts with different dosing regimens, is to determine safety, feasibility, tolerance,

Hospira will initially offer the solution form of oxaliplatin injection in 50mg and 100mg single-use vials, indicated to treat colon and colorectal cancer. Hospira specialty pharmaceuticals, vice president

The agreement will primarily focus on providing biological bases for the development of potential Pfizer compounds for autoimmune disease with an initial focus on Lupus, including characterizing mechanisms

As part of the diabetes alliance between AstraZeneca and Bristol-Myers, AstraZeneca has made an initial payment of $3.2bn to Amylin Pharmaceuticals. Bristol-Myers chief executive officer Lamberto Andreotti said

Synthetic Biologics leverages Intrexon’s suite of proprietary technologies for the discovery of fully human mAbs for the treatment of certain infectious diseases not adequately addressed by existing therapies.